Bristol Myers Squibb Adopts Anthropic’s Claude as Enterprise Intelligence Platform

Bristol Myers Squibb has entered a strategic agreement with Anthropic to implement Claude Enterprise as its shared intelligence platform across global operations, announced in a press release. The collaboration will extend across research, clinical development, manufacturing, commercial, and corporate functions, providing AI-driven reasoning and automation capabilities to more than 30,000 employees.

The deployment will use Claude Code to assist engineering and data science teams in standardizing AI and software development processes. This approach aims to unlock data and expertise within the company’s systems and improve efficiency in building and deploying digital solutions.

Bristol Myers Squibb plans to embed Claude agents into critical workflows such as research, drug development, manufacturing, and medical affairs. These agents will assist with tasks including analyzing proprietary scientific and clinical data, drafting trial documentation, supporting regulatory submissions, and streamlining manufacturing quality processes.

Through secure integrations with internal systems and knowledge repositories, Claude will connect institutional knowledge across departments under full enterprise governance and audit controls. This agreement builds on more than three years of AI investment at Bristol Myers Squibb, which has established the company as an early adopter of advanced AI capabilities in the biopharmaceutical sector.